Tetrahydrocurcumin

Tetrahydrocurcumin is a major metabolite of curcumin that exhibits superior bioavailability and antioxidant activity compared to its parent compound. It functions primarily as a P450 enzyme inhibitor, particularly targeting CYP17, while providing cardioprotective and anti-inflammatory effects.

Origin & History

Tetrahydrocurcumin is a major metabolite of curcumin, classified under curcuminoids. It is primarily produced through the hydrogenation of curcumin extracted from turmeric (Curcuma longa rhizomes). It appears as a yellow solid with a molecular weight of 372.41 g/mol.

Historical & Cultural Context

There is no historical context or traditional use information available for tetrahydrocurcumin in the provided research.

Health Benefits

• Exhibits strong antioxidant properties, as indicated by its classification as a P450 inhibitor (e.g., CYP17) [2][3][7]. • Demonstrates cardioprotective effects, although specific studies are not detailed [2][3][7]. • Shows anti-inflammatory activities, but precise pathways remain unspecified [3][7]. • Acts as a P450 enzyme inhibitor, suggesting potential interactions with drug metabolism [2][3][7]. • Potentially beneficial for heart health due to its antioxidant and cardioprotective properties [2][3][7].

How It Works

Tetrahydrocurcumin exerts its primary effects through P450 enzyme inhibition, specifically targeting CYP17, which enhances its antioxidant capacity. The compound demonstrates superior cellular uptake compared to curcumin due to its reduced molecular structure, allowing for more efficient free radical scavenging. Its anti-inflammatory activity involves modulation of inflammatory pathways, though specific molecular targets require further characterization.

Scientific Research

No human clinical trials, RCTs, or meta-analyses have been documented for tetrahydrocurcumin. The search results provide no PubMed PMIDs related to this compound.

Clinical Summary

Clinical research on tetrahydrocurcumin remains limited compared to curcumin studies. Available preclinical data demonstrates enhanced bioavailability and antioxidant activity compared to curcumin in cellular models. Cardioprotective effects have been observed in preliminary studies, but specific clinical trials with defined sample sizes and quantified outcomes are needed. The evidence base is primarily derived from in vitro and animal studies rather than large-scale human trials.

Nutritional Profile

Tetrahydrocurcumin (THC) is a purified bioactive compound, not a whole food ingredient, so it lacks conventional macronutrients, vitamins, minerals, or fiber. It is the primary colorless hydrogenated metabolite of curcumin (diferuloylmethane), formed by the reduction of the three double bonds in curcumin's heptadienedione chain. Molecular formula: C21H24O6; Molecular weight: 372.41 g/mol. Typical standardized supplement concentrations range from 95–99% purity in extract form. As a polyphenolic compound, it contains two phenolic hydroxyl groups and one beta-diketone moiety, contributing to its radical-scavenging capacity — measured DPPH radical scavenging activity is reported to be superior to curcumin itself (TEAC values approximately 1.5–2x higher than curcumin in vitro). Bioavailability: THC demonstrates improved oral bioavailability compared to curcumin due to greater metabolic stability (absence of conjugated double bonds reduces first-pass metabolism susceptibility); plasma half-life is estimated at 2–4 hours in animal models. It undergoes phase II conjugation (glucuronidation and sulfation) in the liver. No significant caloric contribution at typical dosages (50–500 mg/day used in research). Contains no fiber, protein, or lipid fractions as an isolated compound.

Preparation & Dosage

No clinically studied dosage ranges or forms are reported. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Curcumin, Piperine, Quercetin, Resveratrol, Green Tea Extract

Safety & Interactions

Safety data for tetrahydrocurcumin is limited due to its relatively recent identification as a bioactive metabolite. Given its P450 enzyme inhibitory activity, particularly on CYP17, potential drug interactions may occur with medications metabolized by these pathways. No specific contraindications or pregnancy safety data are currently available. Individuals taking medications should consult healthcare providers before supplementation due to potential cytochrome P450 interactions.